Last reviewed · How we verify

NCT06614803

Study of the Effects of Transcutaneous Auricular Vagus Nerve Stimulation Combined with Slow Breathing on Insomnia

Completed NA Last updated 26 September 2024
What this trial tests

NA trial testing Transcutaneous vagus nerve stimulation combined slow breathing in Insomnia in 80 participants. Completed in 31 July 2024.

Timeline
1 January 2024
Primary endpoint
14 July 2024
31 July 2024

Quick facts

Lead sponsorXidian University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment80
Start date1 January 2024
Primary completion14 July 2024
Estimated completion31 July 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xidian University

Who can join

Adults 18 to 28, any sex, with Insomnia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study recruited college students with insomnia disorders and applied transcutaneous auricular vagus nerve stimulation(taVNS) combined with slow breathing. The main aims of the study are: 1) to explore the role of this novel and effective physical therapy technique of taVNS combined with slow breathing in regulating insomnia; 2) to investigate the relationship between the synergistic effect of taVNS and slow breathing on interoceptive indicators and their therapeutic effects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Insomnia

Currently open trials in the same condition.

Other Xidian University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06614803.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing